Home > Insider Trading > Filing (0000899243-19-028937)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1740547	Urovant Sciences Ltd.	UROV	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1314596	Keith Katkin	C/O Urovant Sciences, Inc. 5281 California Avenue, Suite 100 Irvine CA 92617	Peo;Ceo/Urovant Sciences, Inc.	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2019-12-09	120,000	$3.86	120,000	No	4	M	Direct
Common Shares	Disposition	2019-12-09	120,000	$12.78	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (Right to Buy)	Disposition	2019-12-09	120,000	$0.00	120,000	$3.86

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
881,254		2027-09-21	No	4	M	Direct

Footnotes

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.35 to $12.885. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed to minimize the potential impact of 280G excise tax, which may be triggered by the change of control resulting from the acquisition by Sumitomo Dainippon Pharma Co., Ltd. of Roivant Sciences Ltd.'s ownership interest in the Issuer. Following the reported transaction, the Reporting Person beneficially owns options to purchase an aggregate of 1,596,166 common shares.
25% of the total shares underlying the option vested and became exercisable on September 21, 2018; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.